Navigation Links
Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
Date:6/27/2008

xis' quality of science and productivity," said Paolo Poletti, MD, senior vice president of the Oncology Medicines Development Center at GSK.

"The GSK collaboration was critical to the development of Exelixis' world- class discovery group and our rapidly expanding clinical development group. Today, we have a pipeline of 11 compounds in clinical development, including XL184, which begins a phase 3 trial this summer," said George A. Scangos, president and chief executive officer of Exelixis. "This collaboration has been successful in that both companies have been able to share in the output of our discovery and development efforts and will be able to take forward multiple promising compounds with significant commercial potential in oncology. With the successful completion of the collaboration, we will have clarity regarding the exclusivity obligations under the GSK collaboration and ownership of the compounds in our pipeline."

To date, Exelixis has received approximately $235 million from GSK, which includes $150 million in upfront, milestone, and R&D support payments, and $85 million through a loan facility. Additionally, if GSK selects a second compound for further development, Exelixis will be entitled to receive an additional milestone payment of either $55 million or $27.5 million. The milestone will be due after the selected compound achieves proof-of-concept and will be creditable by GSK against amounts outstanding under the loan facility. Exelixis is eligible for development milestones and royalties on compounds selected for development and commercialization by GSK, which include XL880 and potentially one additional compound if GSK exercises its second development election. Exelixis will pay GSK a low, single-digit royalty on certain "Refused Candidates" that GSK elected not to choose with its development election which Exelixis thereafter successfully commercializes.

Background on Exelixis-GSK Collaboration

In October 2002, Exelixi
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by product ... Table-top Counters) by End-user (Inpatient Pharmacy Automation, Outpatient ... 2019” analyzes and studies the major market drivers, ... and the Rest of the World (RoW). , ... through 300 pages and in-depth TOC on "Pharmacy ...
(Date:10/20/2014)... Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... brings Q3 orders to $5.8 million and provides a good start ... North America and one in the ... new projects at record levels," said Peter Bruijns , President ... the end of Q3 than they have been for any complete ...
(Date:10/20/2014)... OncLive® is pleased ... at Thomas Jefferson University has joined its Strategic ... Alliance Partnership program, the Sidney Kimmel Cancer Center ... awareness of the Center’s cutting-edge research programs, comprehensive ... and other health care professionals from the Sidney ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th ... will take place at the Congress Center ... is now available at http://www.abim.ch . ... organizations from all over the globe will ... latest products and developments on the world ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... Direct, a wholly owned subsidiary of Medco Health Solutions, ... provider of guidance and decision support for genomic medicine, ... Atlantic Health of Morristown, New Jersey, Crittenton Hospital Medical ... Chicago, Illinois, have joined the Genomic Medicine Network to ...
... Chase Cancer Center , one of the nation,s leading cancer research ... data to its website as a tool to assist newly-diagnosed ... on a survey Fox Chase commissioned in the fall of 2010, ... would be the most important in ...
... 31, 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. ("China-Biotics", ... developer, manufacturer and distributor of probiotics products in China, ... 08:00 a.m. Eastern Time/09:00 p.m. Beijing Time on Wednesday, ... third quarter financial results for the period ended December ...
Cached Biology Technology:Four Community Hospitals Join DNA Direct's Genomic Medicine Network 2Four Community Hospitals Join DNA Direct's Genomic Medicine Network 3Fox Chase Cancer Center Publishes Clinical Outcomes for Patient Use 2Fox Chase Cancer Center Publishes Clinical Outcomes for Patient Use 3China-Biotics to Report Fiscal Year 2011 Third Quarter Financial Results on February 9 2
(Date:10/17/2014)... This news release is available in German . ... need millions of sperms every day in order to reproduce? ... questions are the topic of the latest issue of the ... 16th, 2014). The evolutionary biologist Steven Ramm from Bielefeld University ... nature, it is not unusual for a female to copulate ...
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
(Date:10/16/2014)... have challenged conventional thinking on how the bowel lining ... for how bowel cancer starts. , The researchers produced ... regenerating the ,crypts, that are a feature of the ... in bowel cancer development, a controversial finding as scientists ... Using 3D imaging technologies, Dr Chin Wee Tan and ...
Breaking Biology News(10 mins):Sperm wars 2Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2
... - One of the most common house ant species might ... spaces in a forest, but the ants have found ways ... Grzegorz Buczkowski, a Purdue University research assistant professor of entomology, ... complex as they move from forest to city and act ...
... -- Amphibiansfrogs, toads, salamanders, and newtsare disappearing worldwide, but ... be stable. This region is home to the largest ... species reside here), and scientists want to understand what ... research published in the March 29, 2010 issue of ...
... for a gene to create a protein, the gene,s DNA ... These RNA molecules are the instruction manuals that show the ... a protein. A few years ago, scientists studying bacterial cells ... can bind to. In doing so, they induce the RNA ...
Cached Biology News:Common house ants form supercolonies, prosper in urban settings 2Young salamanders' movement over land helps stabilize populations 2Young salamanders' movement over land helps stabilize populations 3Genes under control 2
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Epi-Grids™ Colony Grid Templates are easy-to-use griding templates that allow rapid organization of colonies from initial screening plates and for preparing precise master plates....
Biology Products: